Pyrazole-carboxamide derivatives as modulators of TAAR for use in the treatment of various disorders, such as depression, diabetes and Parkinson's disease

A compound of formula ** ** Formula wherein R1 is phenyl, optionally substituted with halogen, C1-7 alkyl, C3-6 cycloalkyl, C1-7 alkoxy, cyano, C1-7 alkyl substituted with halogen, C1-7 alkyl substituted with hydroxy, C1-7 alkoxy substituted with halogen or C1-7 alkoxy substituted with hydroxy; or is pyridin-2, 3 or 4-yl, optionally substituted by halogen, C1-7 alkyl, C3-6 cycloalkyl, cyano, C1-7 alkyl substituted with halogen, C1-7 alkyl substituted with hydroxy, C1-7 alkoxy, C1-7 alkoxy substituted with halogen, or C1-7 alkoxy substituted with hydroxy; or is pyrimidin-2, 4 or 5-yl, optionally substituted by halogen, C1-7 alkyl, C3-6-cycloalkyl, C1-7 alkyl substituted with hydroxy or C1-7 alkyl substituted with halogen, or pyrazin-2- yl, optionally substituted by halogen, C1-7 alkyl, C3-6 cycloalkyl, C1-7 alkyl substituted with halogen, C1-7 alkyl substituted with hydroxy or cyano, or is 2,2-difluorobenzo [d] [1,3] dioxol-5-yl or thiazolyl, optionally substituted with C1-7 alkyl substituted with halogen; R2 is hydrogen or C1-7 alkyl; R3 is hydrogen, amino or C1-7 alkyl; Z is a bond, -CH2- or -O-; or an addition salt of pharmaceutically suitable acid thereof.